J. Craig Venter, Ph.D., describes biofuels, vaccines and foods from made-to-order microbes

Public release date: 25-Mar-2012 [ | E-mail | Share ]

Contact: Michael Bernstein m_bernstein@acs.org 619-525-6268 (March 23-28, San Diego Press Center) 202-872-6042

Michael Woods m_woods@acs.org 619-525-6268 (March 23-28, San Diego Press Center) 202-872-6293 American Chemical Society

SAN DIEGO, March 25, 2012 Just as aspiring authors often read hundreds of books before starting their own, scientists are using decades of knowledge garnered from sequencing or "reading" the genetic codes of thousands of living things to now start writing new volumes in the library of life. J. Craig Venter, Ph.D., one of the most renowned of those scientists, described the construction of the first synthetic cell and many new applications of this work today at the 243rd National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society, which is underway this week.

In a plenary talk titled, "From Reading to Writing the Genetic Code," Venter described a fundamental shift in his field of genomics, and its promise for producing synthetic life that could help provide 21st century society with new fuels, medicines, food and nutritional products, supplies of clean water and other resources. Venter, a pioneer in the field, led the team at Celera Genomics that went head-to-head with the government-and-foundation-funded Human Genome Project in the race to decode the human genome. This quest, in which the 23,000 human genes were deciphered, ended with the teams declaring a tie and publishing simultaneous publications in 2001.

"Genomics is a rapidly evolving field and my teams have been leading the way from reading the genetic code deciphering the sequences of genes in microbes, humans, plants and other organisms to writing code and constructing synthetic cells for a variety of uses. We can now construct fully synthetic bacterial cells that have the potential to more efficiently and economically produce vaccines, pharmaceuticals, biofuels, food and other products."

The work Venter described at the ACS session falls within an ambitious new field known as synthetic biology, which draws heavily on chemistry, metabolic engineering, genomics and other traditional scientific disciplines. Synthetic biology emerged from genetic engineering, the now-routine practice of inserting one or two new genes into a crop plant or bacterium. The genes can make tomatoes, for instance, ripen without softening or goad bacteria to produce human insulin for treating diabetes. Synthetic biology, however, involves rearranging genes on a much broader scale that of a genome, which is an organism's entire genetic code to reprogram entire organisms and even design new organisms.

Venter and his team at the not-for-profit J. Craig Venter Institute (JCVI), which has facilities in Rockville, Maryland, and San Diego, announced in 2010 that they had constructed the world's first completely synthetic bacterial cell. Using computer-designed genes made on synthesizer machines from four bottles of chemicals, the scientists arranged those genes into a package, a synthetic chromosome. When inserted into a bacterial cell, the chromosome booted up the cell and was capable of dividing and reproducing.

In the ACS talk, Venter described progress on major projects, including developing new synthetic cells and engineering genomes to produce biofuels, vaccines, clean water, food and other products. That work is ongoing at both JCVI and at his company, Synthetic Genomics Inc. (SGI). A project at SGI for instance, aims to engineer algae cells to capture carbon dioxide and use it as a raw material for producing new fuels. Another group uses synthetic genomic advances with the goal of making influenza vaccines in hours rather than months to better respond to sudden mutations in those viruses.

Venter also described his work in sequencing the first draft human genome in 2001 while he and his team were at Celera Genomics, as well as the work on his complete diploid genome published in 2007 by scientists at JCVI, along with collaborators at The Hospital for Sick Children in Toronto and the University of California, San Diego. In addition to continued analysis of Venter's genome, he and his team are also studying the human microbiome, the billions of bacteria that live in and on people, and how these microbes impact health and disease.

Originally posted here:
J. Craig Venter, Ph.D., describes biofuels, vaccines and foods from made-to-order microbes

Professor leaves positive legacy

By Stephen Brooks | Originally Published: 1 hour ago |Modified: 1 hour ago |

Biochemistry professor Rawle Hollingsworth in his lab on Wednesday March 9, 2005.

During biochemistry professor Rawle Hollingsworths nearly 30 years at MSU, Tom Sharkey, chair of the biochemistry and molecular biology department, remembers having many conversations with him during casual run-ins outside the office.

One encounter sticks out in Sharkeys mind, who said he has a strong memory of listening to Hollingsworth explain carbohydrate involvement in blood types one day in the parking lot.

I was just fascinated to learn the things he was explaining, Sharkey said. Its just one of those moments in time that get frozen for reasons that you dont really know why.

Hollingsworth, a 55-year-old Haslett, Mich. resident, died from a pulmonary embolism on Feb. 29.

After completing his doctorate at the University of the West Indies in the Caribbean, Hollingsworth started as an assistant professor at MSU in 1983 and climbed the ranks to become a full professor.

I would say his enthusiasm really was the thing I continually think about when I think of him, Sharkey said.

Rawle Hollingsworth met his wife, Saleela Hollingsworth, at the University of the West Indies. The two were married for 26 years and had two children, Misha, 20, and Akhil, 15.

Saleela Hollingsworth said her husband loved traveling, reading and music and always put the childrens interests first.

View post:
Professor leaves positive legacy

Anatomy of Atomi

ANDREW Tan and his Japanese wife, Mitsuko Murano, found it difficult to find products in Singapore that matched their eclectic tastes and eye for standout designs.

But each time they visited Muranos hometown in Tokyo, they would go on a shopping spree.

Then they thought Why not bring these products to Singapore and open a shop?

Tan ditched his high-flying career at global accounting firm Ernst & Young and Murano gave up her job at an international cosmetic company to start Atomi, which, incidentally, stands for Andrew and Mitsuko in Japanese.

The philosophy behind our store is to promote Japanese design and comfortable lifestyle, says the sweet-natured Murano.

We started out with things we like, products weve been using for a long time that were confident about.

Atomi had a humble start, opening in November 2009 with only five brands to showcase. The couple handpicked products with timeless designs, meticulous handiwork, and those only found in limited quantities or editions. Today, the store offers more than 20 brands including a slew of award-winning designs.

We want to sell something that lasts a long time and not pander to the buy-and-throw culture, explains Murano.

Hence our products are not driven by trends.

Atomi also wants to show their customers that niche, innovative products arent necessarily pricey. At the store, linen items are priced from S$13 (RM31) to S$338 (RM830), ceramic and glassware start at S$43 (RM105) while designer chairs are sold from S$990 (RM2,435) onwards

More here:
Anatomy of Atomi

Bone Marrow Stem Cell Therapy Trial – Clues, But No Answers

(RTTNews.com) - An important clinical trial, which evaluated the use of autologous bone-marrow-cell therapy in patients with chronic ischemic heart failure, has failed to meet the prespecified end points of improvement in most measures of heart function, according to the results presented at the American College of Cardiology 2012 Scientific Sessions.

The trial dubbed, FOCUS - a phase II study, is the largest study to date to investigate if a patient's own bone marrow cells improved myocardial perfusion, reduced left ventricular end-systolic volume or enhanced maximal oxygen consumption in patients with coronary artery disease or LV dysfunction, and limiting heart failure or angina. The FOCUS trial was undertaken by the National Heart, Lung, and Blood Institute-sponsored Cardiovascular Cell Therapy Research Network.

Ninety two patients with chronic ischemic heart disease , having a left ventricular ejection fraction of 45% or less, a perfusion defect by single-photon emission tomography, or SPECT, who were no longer candidates for revascularization, were enrolled in the trial. Sixty one patients in the study were administered bone marrow cells through transendocardial injections while thirty one patients were administered placebo.

An assessment of primary endpoints at 6 months has revealed that there is no statistically significant difference between the treatment group and placebo arm in left ventricular end-systolic volume assessed by echocardiography, maximal oxygen consumption, and reversibility on SPECT. The secondary outcomes, including percent myocardial defect, total defect size, fixed defect size, regional wall motion, and clinical improvement, also has not exhibited any difference between the two arms.

However, according to the study authors, exploratory analyses have revealed that left ventricular ejection fraction improved in the treatment group compared with the placebo group by 2.7%.

The authors, led by Emerson Perin, concluded that the findings provide evidence for further studies to determine the relationship between the composition and function of bone marrow product and clinical end points. Understanding these relationships will improve the design and interpretation of future studies of cardiac cell therapy, the authors noted.

The results were published online March 24 in the Journal of the American Medical Association.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Link:
Bone Marrow Stem Cell Therapy Trial - Clues, But No Answers

How vitamin D helps prevent lung cancer

by: Aurora Geib

Increasing vitamin D may now be a matter of life or death, as recent studies have shown that it may play a vital role in the fight against lung cancer. To date, lung cancer is one of the three most common cancers that kill men and women in developed countries with a statistic of one million deaths every year.

Researchers from the University of California at San Diego discovered a correlative relationship between higher rates of lung cancer and less exposure to the sun.

Cancer and vitamin D

The study compared data from national and international databases and compared the lung cancer rates in 111 countries. It found a correlation with smoking, lung cancer and significant lower UVB exposure. Although the current study focused only on lung cancer, research conducted on other cancers have pointed to the fact that most cancer cases are seen in subjects living far from the equator, suggesting that lower levels of vitamin D also account for a high risk of colon and other cancers. Read more...

AyurGold for Healthy Blood

Source:
http://anti-aging-for-today.blogspot.com/feeds/posts/default?alt=rss

Cancer industry trying to co-opt most recent potential natural cure – frankincense

by: Paul Fassa

"There is not one, but many cures for cancer available. But they are all being systematically suppressed by ... the major oncology centers. They have too much of an interest in the status quo," stated Dr Robert Atkins, MD, creator of the Atkins Diet, after licensure problems for curing cancer patients with ozone therapy during the 1960s.

Yet the cancer industry keeps doing exactly what Dr. Atkins described. It is amazing how many cures do exist while many suffer and die from "accepted" incredibly expensive toxic chemotherapy and radiation treatments.

At least 100 natural cancer cures have been discovered and used successfully without side effects since 1920.

Now independent research points to another potential natural cancer cure, Sacred Frankincense. This is an herb grown mostly in Oman, south of Saudi Arabia and east of Yemen on the Arabian Sea coast. It has been used medicinally for thousands of years for several ailments by Ayruvedic medicine. However, research is being conducted with the goal of isolating active ingredients in the herb that Big Pharma may mimic with lucrative FDA approved patents. Read more...

AyurGold for Healthy Blood

Source:
http://anti-aging-for-today.blogspot.com/feeds/posts/default?alt=rss

Physical Therapist Technician:

Seeking a full-time, experienced Physical Therapist Technician for our progressive, employee centered outpatient clinic located in Marana, AZ. We are also looking to hire per diem Physical Therapist Technicians for all four of our locations in Tucson. Your impact on our organization will be significant in providing support services for our clinicians and extraordinary customer service for our patients. This is an opportunity to stretch and improve your skills.
Responsibilities include: Instructing patients in therapist directed programs, and performing other front office/ physical therapy duties accurately and efficiently. Displaying a professional, courteous, and positive attitude when performing job duties and having the ability to work in a team environment. Our company takes pride in its ability to provide the highest level of customer service. We are looking for a new team member who will aim to ensure that all patients receive the greatest quality of treatment and care.
Qualifications: high school diploma or equivalent; basic typing, English and Math skills; computer proficiency and a minimum of two years of experience with a medical or therapy practice. Bilingual English/Spanish is a plus. Customer service experience required.
Benefits for full time employees include: medical insurance, 401(k) plan, profit sharing, holiday pay and PTO
Please email mail your resumes to resumes@mipts.com

Source:
http://physiologynews.blogspot.com/feeds/posts/default?alt=rss

Fulbright Information Session:

Are you interested in spending a year abroad – taking classes, performing a research project, or teaching English – after you graduate?
Then you should consider applying for the Fulbright Program for U.S. Students. The Fulbright is one of the most prestigious awards available for U.S. students. It is open to individuals from any discipline. The award supports a year in one of over 130countries, during which you can take classes, carry out a research project, or serve as an English Teaching Assistant.
Find out more at the:
Fulbright Program for U.S. Students Information Session
Thursday, March 29 @ 3:30pm
Chavez Building, Room 301, The University of Arizona Campus, Room 301
Open to the entire UA community
Please RSVP to Jeff Thibert, Scholarship Advisor in the Office of Nationally Competitive Scholarships (ONCS) at the UA Honors College, at thibert@email.arizona.edu. Also, be sure to tell Jeff if you can’t attend but would like more information. You can also read more about the Fulbright Program at http://us.fulbrightonline.org/.

Source:
http://physiologynews.blogspot.com/feeds/posts/default?alt=rss

Aurora Announces Joining Hitachi Data Systems Technology Alliance Program

First Aperio and Dell, now Aurora and Hitachi. 

AURORA JOINS HITACHI DATA SYSTEMS TECHNOLOGY ALLIANCE PROGRAM TO OFFER BEST-IN-BREED DATA MANAGEMENT AND DIGITAL PATHOLOGY SOLUTIONS

MONTREAL, QUEBEC, CANADA- March 20, 2012 – Aurora Interactive announced today that it has joined the Hitachi Data Systems Technology Alliance Program.  This will allow Aurora to deliver data management and digital pathology solutions to their clients, giving clients timely control of their data and medical choices.

“Aurora is proud to join the Hitachi Data Systems Technology Alliance Program. Hitachi Data Systems is a globally respected leader in the IT industry, and one of the premier technology and services providers to the medical field. Joining this program will allow us to seamlessly fulfill the needs of our clients who have taken the next step in digital pathology adoption and require universal and vendor neutral mass data management solutions. Our participation in the Hitachi Data Systems Technology Alliance Program is fully aligned with our strategy of universality and interoperability and our commitment to giving our clients control over their data and medical choices. As HDS believes that data drives our world and information is the new currency, Aurora believes that timely and efficient data and information access is the key to better patient care and outcomes,” stated Pierre Le Fèvre, President and Chief Executive Officer, Aurora Interactive.

“Hitachi Data Systems would like to welcome Aurora Interactive to our Technology Alliance Program. We strongly believe in partnering with best-in-breed providers to bring our clients leading technologies to pair with our data management systems. Aurora Interactive is an ideal digital pathology partner for us,” said Dave Wilson, senior director, Global Health Solutions,, Hitachi Data Systems.

About Aurora Interactive Ltd.

Aurora Interactive has developed the leading web based software platform (mScope) for simplification, productivity and ease of communications.  mScope’s Universal Web Viewer has collaborative tools to view medical slides and images anytime, anywhere, regardless of file format.  The software has four applications to aid digital pathology web based communications needs: mScope Education, mScope Clinical, mScope Research and mScope Universal Viewer. Aurora’s mission is to improve patient outcomes and help members of the medical community achieve their full potential by eliminating the learning, diagnostic and collaborative restrictions imposed by time and space. http://www.aurorainteractive.com 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

PathXL Webinar: Biobanking – A New Era

Pathxl logo
4th April 2012, 4.15pmGMT /11.15amEST /8.15amPST /5.15pmCET

PathXLTM Biobank is a highly configurable sample collection, tracking, storage, management and distribution platform that provides the flexibility required to build customised solutions across a range of biobank applications. 

As well as providing a complete biobank management solution, PathXLTM Biobank is also available in the form of a virtual microscopy plug-in to existing biobank solutions enhancing its functionality and efficiency.Biobank pic

Guest Speaker:  

PathXLTM Biobank was developed in partnership with the Northern Ireland Biobank; Dr Jackie James (Northern Ireland Biobank Scientific Lead) provides a customer insight. 

Why Attend?

This is the world’s first biobank platform with an inbuilt image management and viewing platform specifically for virtual slides.  Find out how you can manage collection, tracking and distribution of all samples in your biobank and see how easily researchers can search, review and request samples online.

Click here to register

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

“I signed out 15 cases from 35,000 feet.”

 

35000

On page 18 of this months' CAP Today within in article dedicated to "AP IT" is an ad from PathCentral mentioning the work of Dr. Greg Henderson and using onboard Wi-Fi, the ability to acccess a web-based LIS solution and review whole slide images from 35,000 feet as part of a non-profit health care initiative. 

 

Talk about cloud computing.  

Mobile devices, ubiquitous high speed bandwidth and web-based LIS systems allow for slide review and diagnoses independent of geography, even if you are flying over a fly-over state.

Check out the free online CAP Today publication for thoughts from many on the current state of "AP IT" and CAP Today's review of AP LIS systems this month. 

 

 

 

 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Aperio Announces Strategic Collaboration with Dell to Create Cloud-Based Services for Pathology

More news from USCAP week -- Aperio partners with Dell to create secure cloud for an electronic pathology network.  Aperio, in addition to providing slide scanners and associated software products for case management, viewing and image analysis is entering into providing a platform with a trusted server partner to facilitate collective intelligence around the globe. 

One of the keys to adoption remains making the process and processes "as fast as glass".  If this truly does shorten TAT for consults, further strengthening the case for e-Patholology solutions, as Dr. Epstein suggests below, another barrier is overcome. 

Example of a perfect storm for digital pathology - higher speed reliable scanners, reduced costs, faster, more reliable networks and storage through cloud computing and web-based viewing, analysis and reporting are highlighted by this collaboration.

Dell’s Unified Clinical Archive Cloud to Power Aperio ePathology Network™

VISTA, Calif., Mar 19, 2012 (BUSINESS WIRE) -- Aperio, the leading provider of digital pathology systems, announced a strategic collaboration with Dell to create the world’s first scalable, secure medical cloud network for Pathology.

Through its secure cloud-based Unified Clinical Archive solution, Dell manages nearly 5 billion medical images and studies for healthcare organizations. And now, Dell will host the existing suite of Aperio’s industry-leading solutions for digital pathology. Fortified by Dell’s standards-based technology and storage capabilities, Aperio’s ePathology Network™ solution will provide secure, compliant, worldwide access to pathology consultations via the cloud.

“Our goal is to address the regional and global imbalances of pathology expertise available for patient care by enabling access to pathologists for all types of consultations, regardless of location. With Dell’s cloud-based archiving platform, we can make our ePathology Solutions™ more widely available,” said David Schlotterbeck, CEO of Aperio.

“This state-of-the-art ePathology Network technology from Aperio will revolutionize the practice of secondary consultations,” states Dr. Jonathan Epstein, Director of Surgical Pathology at Johns Hopkins. “We fully expect that the time to return an opinion on these cases will be significantly reduced -- from multiple days to as a few as a couple of hours in critical cases. This will have a significant positive impact on patient care.”

Dell and Aperio are also collaborating to develop the world’s leading repository of characterized digital slide images and cases, which will include the Juan Rosai Collection of Surgical Pathology Seminars. This furthers another mission of Aperio to make quality educational and reference materials more readily available to all pathologists around the world. The eSlide Repository™ will be a fulcrum for the healthcare and life sciences industries’ focus on personalized medicine and enhanced precision and predictability.

“Dell is excited to work with Aperio to facilitate the archiving and sharing of whole slide pathology images via the cloud,” said James Coffin, Ph.D., vice president and general manager of Dell Healthcare and Life Sciences. “This is a prime example of how on-premise and cloud-based solutions with application-neutral data management capabilities can break down traditional information silos and allow healthcare organizations to securely manage, store and share data to advance patient care.”

About Aperio

For over a decade, Aperio has advanced the technology that enables glass slides to be digitized and securely shared with others. Aperio products are transforming the practice of pathology in hospitals, reference labs and pharmaceutical and research institutions around the world. From the moment glass slides are elevated to eSlides, Aperio ePathology Solutions equip pathologists with the power to evaluate, engage and excel like never before. The NETWORK enables remote, simultaneous, real-time viewing and easy distribution for consults and collaboration. PRECISION tools empower pathologists with advanced analytic capabilities. An interoperable, scalable and secure web-based software platform facilitates integration with existing systems. With Aperio ePathology Solutions, organizations can optimize their pathology operations for transparency, consistency and efficiency to support patient care, personalized medicine and research. For clearance updates, specific product indications, and more information please visit http://www.aperio.com .

SOURCE: Aperio

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Parascript Offers Greater Accuracy in Detecting Breast Cancer

Parascript-LOGO

Parascript, LLC, an image analysis and pattern recognition technology provider, announced that its AccuDetect® Galileo computer-aided detection software for digital mammography showed better overall performance in detecting breast cancer in a recent retrospective study against iCad's SecondLook. Findings from the study, performed at Maastricht University Medical Center departments of Radiology and Surgery in the Netherlands, with collaboration from University of Udine's Institute of Diagnostic Radiology in Italy, were presented at the annual meeting of the European Society of Radiology, ECR, on March 3.

In the study, digital mammograms of 326 patients were analyzed (117 patients with biopsy proven breast cancer, 209 negative cases) using AccuDetect Galileo 4.0 and SecondLook version 7.2. AccuDetect Galileo significantly increased true positive fraction (TPF) of cancer cases when compared to SecondLook. It demonstrated a per image increase of 6.9% to 72.2%; per case increase of 4.3% to 84.6%. The University of Maastricht team noted that AccuDetect Galileo had a significant performance improvement in detecting soft tissue densities on extremely dense breasts (BI-RADS breast density class 4) over SecondLook, increasing TPF by15.4% to 69.2%. Dense breast tissue can obscure an underlying cancer, or conversely mimic one that does not exist, thus making accurate detection difficult.

"We are encouraged by the results of this new study," said Yuri Prizemin, director of business development for medical imaging for Parascript. "We believe that Parascript CAD advancements in marking malignant lesions on extremely dense breasts will help radiologists to improve breast cancer detection."

Full findings from the study were presented by the study authors M. Lobbes, K. Keymeulen, M. Smidt, R.G. Beets-Tan, J.E. Wildberger, and C. Boetes from Maastricht University and R. Girometti and C. Zuiani from University of Udine in Retrospective Comparison of the Accuracy of Two Different Computer-aided Detection Systems for Detecting Malignant Lesions on Mammography.

About Parascript, LLC
The Parascript image analysis suite extracts meaningful information from images. Employing patented digital image analysis and pattern recognition technologies, the Parascript image analysis suite improves decision quality in medical imaging, postal and payment automation, fraud detection and forms processing operations. Parascript software processes billions of documents per year. Fortune 500 companies, postal operators, major government and financial institutions rely on Parascript products. Organizations include the U.S. Postal Service, Bell + Howell, Fiserv, Elsag, Lockheed Martin, NCR, Siemens and Burroughs.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Apollo To Interface ViewsIQ’s Panoptiq™ With Apollo EPMM®

More news during week of USCAP:

Apollo Logo_2 color

Falls Church, VA – March 19, 2012 – Apollo, the leading provider of collaborative clinical multimedia management solutions for the healthcare industry, today announced that it has entered into an agreement with ViewsIQ to interface Panoptiq™, an innovative slide imaging technology, with Apollo’s Enterprise Patient Media Manager (Apollo EPMM®). 

 

Apollo EPMM brings together all clinical media related to an individual patient from throughout the medical enterprise and makes it immediately and easily available to authorized personnel.  This gives healthcare professionals the ability to securely collaborate while using their own best practices. The result is a more integrated clinical team, a dramatic increase in workflow efficiency and effectiveness, and improved patient outcomes at a lower cost.

For laboratory applications, Apollo's solution automatically collects media such as digital slides, gross images, cytology and other imaging modalities from the original source.  Cross-referenced with pictures, videos and other media from multiple specialties throughout the enterprise, pathologists and clinicians get a complete picture of the patient on demand, in a secure, compliant form that enables real-time consults.

ViewsIQ Panoptiq enables pathologists to create panoramic images of their slides in real-time at extremely high resolution with their own microscopes. Trialed by top pathologists at premier healthcare institutions in Canada, Panoptiq integrates seamlessly with the workflow of the pathologist. With Panoptiq, pathologists can see and communicate the microscopic view of the slide more effectively and conveniently.

 “The interfacing of Panoptiq with Apollo EPMM will dramatically enhance the clinical image integration and management capabilities for pathologists and laboratory users,” said Mark Newburger, Apollo CEO, “as well as enabling healthcare providers across the enterprise to access these images immediately.”

“The ability for healthcare providers to access Panoptiq images securely from any location adds significant value to patient care.” said Herman Lo, CEO of ViewsIQ. “With the inclusion of Panoptiq in the total Apollo EPMM solution, we can now offer a robust and comprehensive management, access and storage solution for Panoptiq slide images.” 

About Apollo

Apollo EPMM is an enterprise-wide solution that enables all authorized providers in the healthcare chain to collaborate for the benefit of the patient.  Apollo's EPMM uses the providers’ own best practices by incorporating systems already in place and adds the ability to consult in real-time with the entire clinical team in a cost- effective, flexible, compliant and secure environment.   While others promise easy, secure, specialty-specific access throughout the enterprise, Apollo delivers it today at marquis institutions throughout the United States and Canada.  For more information visit http://www.apollopacs.com and follow us on Twitter. Visit Apollo at USCAP Booth #317.

About ViewsIQ

 ViewsIQ is a Canadian healthcare technology company that develops microscopy imaging solutions for academic institutions and clinical laboratories. Its recent innovation called Panoptiq enables pathologists to create and view panoramic images of their slides in real-time with no delay to their workflow. Healthcare and academic institutions in North America are adopting Panoptiq at a growing pace. For more information please visit our website at http://www.viewsiq.ca, and follow us on Twitter and YouTube.  Visit ViewsIQ at USCAP Booth #814.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Definiens Expands Stereology Capabilities for Quantitative Digital Pathology

Munich, Germany, March 19, 2012 / B3C newswire / Definiens®, the leading provider of image analysis and data mining solutions for quantitative digital pathology, today announced it will expand its already comprehensive product portfolio with additional stereological analysis methods. Stereology can be incorporated into both manual and automated whole slide image analysis workflows. Find more under http://info.definiens.com/stereology.html.

Stereology complements the unique combination of flexibility and ease-of-use that makes Definiens Tissue Studio® the leading solution for analyzing histological samples. With the latest release of Definiens Tissue Studio 3.5, systematic random sampling is now available out of the box.

High productivity through end-to-end automation is achieved by combining stereological methods with Definiens’ automated and precision detection of structure and morphology in heterogeneous tissue. This significantly reduces user interaction and analysis time and delivers unbiased and detailed readouts at the same time. Alternatively, semi-automatic or manual stereology workflows can be applied wherever appropriate.

For three dimensional measurements, Definiens also offers automated co-registration of serial tissue sections. Definiens stereology solutions are compatible with all major slide image file formats on the market and work with both bright field and fluorescence image data.

“Stereological methods are a long established approach to obtaining quantitative data about three-dimensional features from two dimensional tissue sections,” says Thomas Heydler, CEO, Definiens. “Definiens’ offerings in image and data analysis provide biomedical professionals with tools to significantly accelerate workflows and retrieve unparalleled insights from tissue samples.”

Visit Definiens at the USCAP’s industry exhibition, booth number 807, Vancouver, Canada, from March 17—23, 2012.

 

Link to the press release

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

DigiPath Adds 10 Upgrade Options to PathScope

DigiPath, Inc®, a provider of affordable, innovative and reliable digital pathology solutions, announced today that it has added 10 innovative upgrade options to PathScope™, the $24,999 single slide scanning system.

PathScope™ can be configured with 1, 2, 4, or 30 slide capacities.   The capacity configurations range from $24,999 to $54,999.

Users can configure the three objective slots with a 2x, 2.5x, 5x, 10x, 20x, 40x, and 63x dry lens.  The dry objective configurations range from $24,999 to $39,999.

PathScope™ can also support 50x or 100x oil lens.  These oil scanning solutions are priced at $39,999 to $49,999.

“DigiPath continues its innovation by adding greater capacity and dry and oil objective lens solutions,” said Eric Stoppenhagen, President of DigiPath, Inc. “DigiPath also continues to show that customers can adopt digital pathology solutions from $24,999 to $54,999, which is the most affordable offering in the marketplace.”

About DigiPath, Inc.

DigiPath, Inc. provides the next generation of affordable, innovative, and reliable digital pathology solutions.  DigiPath’s advisors bring over 60 years combined expertise in pioneering digital pathology, implementing over 500 installations at community pathology practices, hospitals, academic medical centers, reference laboratories, biopharma organizations, and life science research institutions worldwide.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

ASCP Becomes Managing Partner for ADASP

The American Society for Clinical Pathology (ASCP) and the Association of Directors of Anatomic and Surgical Pathology (ADASP) signed a Memorandum of Understanding (MOU) effective March 15 for ASCP to manage the day-to-day activities of ADASP, so its leaders can conduct business more efficiently. Previously, ADASP volunteers handled both administrative and strategic functions. The MOU also fosters greater collaboration for both organizations' educational and scientific activities in support of anatomic pathology and the broader pathology community.

"Our partnership with ASCP creates new opportunities for our members to be fully engaged and focused on strategic planning," said ADASP President Jeffrey L. Myers, MD, FASCP, A. James French Professor and Director of Divisions of Anatomic Pathology and Medical Laboratories, University of Michigan, Ann Arbor, Mich. "The MOU creates the capacity for our organization to think and do big things. We found a great partner in ASCP."

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

IMRT referral triples after urology group purchases IMRT machine

This post is courtesy of The Pathology Blawg, formerly The Pathology Malpractice Blog.  In addition to discussing medicolegal issues in the world of pathology, The Pathology Blawg also provides material about physician self referral, markups, client billing, pod labs and other unscrupulous maneuvers that negatively impact patient care, contribute to overutilization and damage the profession of pathology, with the hope that greater awareness will bring an end to these practices.

IMRT machine aka ATM machine

This is an article from the Baltimore Sun about Chesapeake Urology Associates' (CUA) use of Intensity Modulated Radiation Therapy (IMRT) for prostate cancer.  Before 2007, they referred 12% of their Medicare patients for IMRT, but amazingly, starting in 2007, their referral rate more than tripled to 43%.  Why the difference?  They bought an IMRT machine in 2007, and now they can bill for the treatments.  Our good friend Dr. Jean Mitchell is interviewed for the piece, and she states the obvious:  This is a way for urology groups to simply make a ton of money off of their patients.  Interestingly, Dr. Mitchell states that CUA's doctors are "some of the less egregious", as many urology groups send around 70% of their patients to IMRT machines they own.

CUA would only speak through their attorney (which is never a good sign), who said,

CUA's doctors are well-respected physicians of the highest integrity," said Howard R. Rubin, the attorney. "They reject any insinuation by you or Prof. Mitchell that any recommendations relating to a patient's care are motivated by anything other than the best interests of the patient.

Which leads me to my question.  If this level of referral (43%) for IMRT is the referral rate the group has decided is in the best interests of their patients, then why did so many patients not get referred for IMRT prior to the group's purchase of the machine?  Why did they not take more of their patient's best interests into account before they owned the machine?

It's all smoke and mirrors.  Keep in mind that urology offices also routinely own their own CT scanners and pathology labs.  They have perfected vertical integration of the diagnosis and treatment of prostate cancer and the commoditization of prostate cancer patients.

Maryland, as the article states, is starting to crack down heavily on self referral, and has already forced orthopedists to sell their in office MRIs.  Raise your hand if you think CUA's IMRT referral rate will drop if Maryland gets around to banning self referral for IMRT.  My hand is up.

http://articles.baltimoresun.com/2012-01-17/health/bs-bz-hancock-chesapeake-urology-20120114_1_imrt-prostate-cancer-cancer-treatments 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Sue Jeiven's Anthromorphic Mouse Taxidermy Class, Valentine's Day Edition






Above are some photos from the recent Valentine's Day edition of our most popular and most often sold out of Observatory class, Anthropomorphic Mouse Taxidermy Class with Susan Jeiven. Sue was recently profiled by the Spanish Television network Telemundo in a piece entitled "Pasatiempos controversial: Disecan animales muertos para decorar;" you can view it in its entirety by clicking here.

For those interested in studying with Sue, in making your own pieces and learning this largely lost Victorian art: I am pleased to announce a few rare vacancies in some upcoming classes; click here to find out more. Click on images to see larger versions; you can also see more photos from past classes by clicking here.

Source:
http://morbidanatomy.blogspot.com/feeds/posts/default?alt=rss